Anacetrapib Developed to Prevent Cardiovascular Disease


anacetrapibAnacetrapib CAS# 875446-37-0, is a CETP inhibitor being developed by Merck to treat hypercholesterolemia, or elevated cholesterol. Clinical trials reported by Merck have been encouraging. In late 2010 researchers from Merck reported a staggering 138% increase in good cholesterol, as well as a 40% drop in bad cholesterol among patients taking Anacetrapib. This trial involved 1,623 patients, and Anacetrapib is now poised to be one of the next generation cholesterol drugs in the market.

The results of the 2010 study show a potential alternative treatment for patients suffering from not only coronary artery disease, but also those patients with diabetes. The proven ability of Anacetrapib to increase high-density lipoprotein (HDL) cholesterol among these high-risk patients is crucial, as these patients are at  a high residual risk for a cardiovascular event to occur.

Studies of Anacetrapib done in 2007 included trials using doses of 10 milligrams, 40 milligrams, 150 milligrams and 300 milligrams. A recent study, conducted by Ronald Krauss (Children’s Hospital Oakland Research Institute, California, USA) and colleagues included once a day treatments, of either 20 milligrams or 150 milligrams for thirty patients. This study showed both doses to be effective, with the 150 milligram dose offering slightly more efficacy. The current clinical trial, coined REVEAL is underway, which encompasses 30,000 patients.

LGM Pharma is a provider of the API Anacetrapib for research and development purposes.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: